2 promising clinical stage assets, with one entering PH3 after approval from regulatory agencies. Eftilagimod alpha is an APC activator leveraging LAG-3’s ligand MHCII to increase both innate and adaptive immune response. This is a pan therapy, as in its benefit is across indications and in combination with any therapy causing tumor debris. This isn’t just a Keytruda enhancer, you’ll see.
Overnight Market report, page-2840
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.020(7.41%) |
Mkt cap ! $421.8M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.5¢ | 27.0¢ | $1.138M | 3.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63444 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 65000 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |